Frédérique Menzaghi
2017
In 2017, Frédérique Menzaghi earned a total compensation of $1.5M as Chief Scientific Officer and Senior Vice President, R&D at Cara Therapeutics, a 93% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $200,000 |
|---|---|
| Option Awards | $917,949 |
| Salary | $379,935 |
| Other | $8,100 |
| Total | $1,505,984 |
Menzaghi received $917.9K in option awards, accounting for 61% of the total pay in 2017.
Menzaghi also received $200K in non-equity incentive plan, $379.9K in salary and $8.1K in other compensation.
Rankings
In 2017, Frédérique Menzaghi's compensation ranked 6,967th out of 14,666 executives tracked by ExecPay. In other words, Menzaghi earned more than 52.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,967 out of 14,666 | 53rd |
Division Manufacturing | 2,582 out of 5,772 | 55th |
Major group Chemicals And Allied Products | 837 out of 2,075 | 60th |
Industry group Drugs | 650 out of 1,731 | 62nd |
Industry Pharmaceutical Preparations | 510 out of 1,333 | 62nd |
Source: SEC filing on April 24, 2019.
Menzaghi's colleagues
We found two more compensation records of executives who worked with Frédérique Menzaghi at Cara Therapeutics in 2017.
News
Cara Therapeutics CEO Derek Chalmers' 2021 pay jumps 250% to $10M
April 22, 2022
Cara Therapeutics CEO Derek Chalmers' 2020 pay slips 15% to $2.9M
April 23, 2021
Cara Therapeutics CEO Derek Chalmers' 2019 pay jumps 23% to $3.4M
April 22, 2020
Cara Therapeutics Chief Medical Officer Joana Goncalves receives $3.7M in 2018
April 24, 2019